ann product pharmedium memphi facil remain suspend even
though expect resum due difficulti determin timelin
longer assum contribut facil model lower pt
despit memphi issu posit thesi remain intact particularli
core pharma remain solid foot
product pharmedium memphi facil remain suspend
announc product pharmedium memphi outsourc facil remain
voluntarili suspend compani complet certain remedi measur
commun fda plan provid updat fda upon
complet remedi measur management intend provid financi updat
report tuesday may recal last quarter earn call
management note voluntarili suspend product activ memphi facil
decemb order fulli compli fda regul new
compound polici prioriti neg impact adj oper
incom management expect facil resum oper product
ramp second half exit fiscal year full product
time difficult gaug outsid look
given entir outsourc facil sector new difficult determin
averag timelin could look like remedi think look hospira
complianc issu could serv worst case scenario gener inject plant could
consid compar outsourc facil hospira deal
complianc issu five year issu fda trigger shutdown
seem minor moreov consult note fact yet
follow-up action fda could neg sign presum least
warn letter come potenti someth wors typic enforc
action come end shutdown process spell path reopen
think resumpt product pharmedium memphi facil like
still pharmedium scale fda support compound could lead
due fda priorit compound think agenc like eager
get memphi facil run particularli given rel larg scale
pharmedium compound industri furthermor compound program
dedic user fee least mean time respons
fda inspector clean occur memphi facil could come back on-line
quickli compar gener manufactur similar problem
pleas see page report import disclosur
posit think on-going transit custom new
price model break specialti result margin expans drive growth
profit addit sourc benefit wbad help drive margin
profit medium-term volum esrx onboard onboard
store acquir also serv near-term tailwind
 statu remedi
 top-lin growth driven specialti
includ alliancerx acquisit hd
smith store acquir
 gross margin
 ebit margin
 top-lin growth low-teen due
greater expect growth specialti
 gm due better
 sg better expect due
 share come lower due greater
expect share repo
 top-lin growth mid-singl digit
due slower slower onboard
store acquir lower brand
 margin closer due higher
expect gener deflat lower
 sg come wors expect
 share come higher due lower
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
updat estim price target impli valuat still attract current
conserv exclud contribut memphi facil updat
model lower adj ep estim
respect lower adj ep estim
respect updat adj ep estim share
still trade attract valuat exclus memphi facil also lower
price target base revis dcf analysi impli
attract upsid current level furthermor upsid price target
memphi facil resum product
figur pharmedium impact estim
cowen compani
despit setback pharmedium posit thesi remain intact
despit setback pharmedium reiter posit thesi
particularli core pharma busi remain solid foot gener deflat
stabil show sign improv addit continu
realiz benefit differenti price strategi result greater
compens specialti break specialti broader brand
drug categori convert contract differenti price
arrang also see potenti upsid sooner expect ramp
econodisc onto wbad improv gener procur capabl
million except per share data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per share data
compani file cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per share data
compani file cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani file cowen compani
chang basi earn basi chang basi earn basi cowen
million
compani file cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani file cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani file cowen compani
activitiesnet incom discontinu incom continu reconcil net incom provis loss account provis defer incom employe stock loss dispos properti impair charg equiti invest -- -- -- lifo expens -- -- -- -- -- pension settlement -- -- -- -- -- includ intang asset loss earli retir debt -- -- -- -- loss sale discontinu op -- -- -- -- -- -- cumul effect account chang net -- -- -- -- -- -- chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom cash provid use oper activ continu cash provid use oper activ discontinu cash provid use oper activitiescapit acquir compani net cash sale properti -- equiti invest -- -- -- sale-lease-back transact -- -- -- -- -- -- proce sale busi -- -- -- -- purchas invest secur avail sale -- -- -- -- sale invest secur -- -- -- -- -- -- -- -- -- -- cash provid use invest activ continu cash provid use invest activ discontinu -- -- net cash provid use invest activitiesborrow revolv securit credit facil -- -- -- -- -- -- proce borrow relat pmc distribut -- -- -- -- -- -- long-term debt borrow -- -- -- -- long-term debt repay -- -- -- -- purchas treasuri financ cost -- exercis warrant -- -- -- -- -- stock dividend common cap call option -- -- common stk purchas employe stock purchas plan net -- -- -- -- -- -- -- -- -- -- cash provid use financ activ continu cash provid use financ activ discontinu -- -- othernet cash provid use financ cash cash cash equival begin cash equival end year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
